The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis
about
HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disordersResidual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density LipoproteinGeneration and biological activities of oxidized phospholipidsAmelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.Biological properties of apolipoprotein a-I mimetic peptides.Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasmaIn vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer.The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges.The regulation of valvular and vascular sclerosis by osteogenic morphogensABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis.Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids.Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.Effects of an Aβ-antibody fragment on Aβ aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides.Cholesterol efflux in the transplant patient.
P2860
Q27691344-40438B1D-8D4C-4F18-9B9F-EBCCB53FD0BAQ28083619-ECE2B16E-8C67-4DB7-9A76-434A95B65B22Q28389691-486D658F-4322-4EFC-A296-C281C9F4DD17Q34308238-22E577CD-298F-443B-BF54-E406AFCD02BCQ34927488-09E9BC9E-C27F-4DE3-BB73-33BF9DD70BB7Q35212906-27C70BEA-A0DC-4431-BDC0-265FAE7439C8Q35760064-28F368C6-005D-48E9-8763-94F582EB7604Q36028380-802888DD-4498-4F13-86E0-FF859D9FF151Q37346790-72AC873D-D899-431B-934C-21433CB23717Q37919693-534F88A4-5F0E-4C9A-81BE-AE0D6AF8D8C2Q41305436-E04CF565-8F84-43F2-BBFE-C867CA10EBE7Q41974849-06624646-01DF-4DF5-8274-8974738DCAF7Q42562376-B89B8C3B-0A67-425A-B735-9DA56E549951Q47125219-81EEF5AC-06A5-497D-B266-1A6286E155ECQ50027499-AC01536A-A493-4411-9435-849F3D341349
P2860
The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The effect of apolipoprotein m ...... ers other than atherosclerosis
@en
The effect of apolipoprotein m ...... rs other than atherosclerosis.
@nl
type
label
The effect of apolipoprotein m ...... ers other than atherosclerosis
@en
The effect of apolipoprotein m ...... rs other than atherosclerosis.
@nl
prefLabel
The effect of apolipoprotein m ...... ers other than atherosclerosis
@en
The effect of apolipoprotein m ...... rs other than atherosclerosis.
@nl
P2093
P2860
P1476
The effect of apolipoprotein m ...... ers other than atherosclerosis
@en
P2093
Alan M Fogelman
G M Anantharamaiah
Mohamad Navab
P2860
P356
10.1016/J.TCM.2007.12.006
P577
2008-02-01T00:00:00Z